Comparative Pharmacology
Head-to-head clinical analysis: AIRSUPRA versus AZMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRSUPRA versus AZMACORT.
AIRSUPRA vs AZMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIRSUPRA is a fixed-dose combination of albuterol (a short-acting beta2-agonist) and budesonide (an inhaled corticosteroid). Albuterol relaxes bronchial smooth muscle via beta2-adrenergic receptor activation, increasing cAMP and causing bronchodilation. Budesonide reduces airway inflammation by binding to glucocorticoid receptors, modulating gene transcription to suppress inflammatory mediators.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
2 inhalations (albuterol 180 mcg / budesonide 160 mcg) orally inhaled twice daily (morning and evening), maximum 2 inhalations twice daily.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
None Documented
None Documented
Budesonide: 2-3 hours; formoterol: 10-14 hours; clinical context: steady state achieved within days for both
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Budesonide: ~60% renal as metabolites, ~40% fecal; formoterol: ~60% renal, ~40% fecal
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Category C
Category C
Inhaled Corticosteroid/SABA Combination
Inhaled Corticosteroid